Crohn’s patients seek cannabinoid approvals because they have already found that it changes the course of their disease. After seeing the first several patients reporting marked improvement in their conditions with the use of cannabinoids other groups began reporting the same significant change.

All surveyed patients with Crohn’s disease report statistically significant improvement in signs and symptoms in all categories: pain in the gut, anorexia, nausea, vomiting, fatigue, depressed mood, and activity level. Based on a recent Israeli clinical study cannabinoids reduced pain in the gut more so than the pharmaceuticals that were provided. The number of stools per day was reduced, the body weight increased, and all patients reported the frequency and severity of flare-ups were reduced. Through the use of hemp many have seen these side effects reduce or completely become eliminated as the patient begins to embrace cannabinoid therapeutics.

It is now known that biopsy specimens from Crohn’s patients had large quantities of cannabinoid receptors. Activating these receptors with cannabinoids promoted healing of the gastrointestinal membrane. This could offer therapeutic relief to patients suffering from inflammatory disorders such as Crohn’s disease and ulcerative colitis.